Another piece of good news for the "miracle drug" for weight loss! Lilly's (LLY.US) Trulicity reduced the risk of diabetes in obese people by 94%.
During a three-year trial, tirzepatide reduced the risk of type 2 diabetes by 94% in adults with prediabetes, obesity or overweight.
Tirzepatide, the active ingredient in Eli Lilly's (LLY.US) diabetes drug Mounjaro and weight-loss drug Zepbound, was found to significantly reduce the risk of type 2 diabetes by 94% in adults with prediabetes, obesity or overweight.
The SURMOUNT-1 study, which assessed tirzepatide in 1,032 adults with prediabetes, obesity or overweight, had a 176-week treatment period, followed by a 17-week post-treatment follow-up (total 193 weeks).
Compared with placebo, weekly injections of tirzepatide (5mg, 10mg, 15mg) significantly reduced the risk of type 2 diabetes by 94% in adults with prediabetes and obesity or overweight.
In addition, tirzepatide maintained weight loss throughout the treatment period. At the end of the treatment period, patients with prediabetes and obesity or overweight taking 15mg had an average weight loss of 22.9%, compared with 2.1% in the placebo group.
During the 17-week post-treatment follow-up, weight began to increase in patients who had stopped taking tirzepatide, and the risk of developing type 2 diabetes increased, but was still 88% lower than placebo.
As of the close, Eli Lilly was up 1.8%, while Novo Nordisk (NVO.US) was down 0.11%.